Chimerix, Inc. Forecasted to Earn Q2 2024 Earnings of ($0.27) Per Share (NASDAQ:CMRX)

Chimerix, Inc. (NASDAQ:CMRX) – Equities research analysts at Capital One Financial issued their Q2 2024 earnings per share estimates for shares of Chimerix in a research note issued on Wednesday, May 1st. Capital One Financial analyst N. Quibria forecasts that the biopharmaceutical company will post earnings of ($0.27) per share for the quarter. The consensus estimate for Chimerix’s current full-year earnings is ($0.81) per share. Capital One Financial also issued estimates for Chimerix’s Q3 2024 earnings at ($0.28) EPS, Q4 2024 earnings at $0.05 EPS, FY2024 earnings at ($0.74) EPS, FY2025 earnings at ($1.10) EPS, FY2026 earnings at ($0.62) EPS and FY2027 earnings at ($0.56) EPS.

Several other equities analysts have also recently issued reports on the company. HC Wainwright restated a “buy” rating and set a $11.00 price objective on shares of Chimerix in a research note on Friday, March 1st. Wedbush restated an “outperform” rating and issued a $6.00 price target on shares of Chimerix in a research report on Monday, February 12th. Finally, StockNews.com downgraded shares of Chimerix from a “hold” rating to a “sell” rating in a research report on Friday, May 3rd.

Chimerix Trading Down 1.0 %

Shares of CMRX opened at $0.99 on Monday. Chimerix has a 52 week low of $0.88 and a 52 week high of $1.57. The firm has a market cap of $88.73 million, a price-to-earnings ratio of -1.06 and a beta of 1.13. The stock has a 50 day moving average of $1.03 and a 200-day moving average of $1.00.

Chimerix (NASDAQ:CMRX) last issued its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.04). Chimerix had a negative net margin of 25,337.96% and a negative return on equity of 41.32%. During the same quarter last year, the business posted ($0.24) earnings per share.

Institutional Trading of Chimerix

A number of large investors have recently modified their holdings of the company. Marquette Asset Management LLC grew its position in Chimerix by 24.3% in the 1st quarter. Marquette Asset Management LLC now owns 116,009 shares of the biopharmaceutical company’s stock worth $123,000 after purchasing an additional 22,709 shares during the last quarter. Vance Wealth Inc. acquired a new position in shares of Chimerix during the fourth quarter worth approximately $46,000. Assenagon Asset Management S.A. grew its holdings in Chimerix by 17.0% in the 4th quarter. Assenagon Asset Management S.A. now owns 499,391 shares of the biopharmaceutical company’s stock worth $481,000 after buying an additional 72,719 shares in the last quarter. Pale Fire Capital SE acquired a new stake in Chimerix in the 3rd quarter valued at approximately $95,000. Finally, Bank of New York Mellon Corp raised its stake in Chimerix by 190.0% during the 3rd quarter. Bank of New York Mellon Corp now owns 591,697 shares of the biopharmaceutical company’s stock valued at $568,000 after acquiring an additional 387,638 shares in the last quarter. Institutional investors and hedge funds own 45.42% of the company’s stock.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.